The Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code (J7354) for Verrica’s YCANTH, a molluscum contagiosum treatment.
Under the Healthcare Common Procedure Coding System (HCPCS) process, the J-Code for YCANTH will become fully published April 1, 2024.
“By securing a permanent J-Code for YCANTH, we have successfully reached a critical milestone in our commercial strategy that we expect will help us accelerate YCANTH utilization among the U.S. Medicaid and Medicare patient populations,” says Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, in a news release. “In addition to greater patient access, we also anticipate a permanent J-Code will result in a more streamlined billing and reimbursement process for YCANTH.”
J-codes are a type of HCPCS Level II code commonly used to designate non-orally administered drugs and other medical devices. J-codes help determine how managed care organizations reimburse medical providers for products and services. J-codes allow providers to use the same code across all payers for reimbursement. Using a standardized code reduces the risk of billing errors and allows companies to receive pass-through payments through government-sponsored healthcare plans.
